/odishatv/media/agency_attachments/2025/07/18/2025-07-18t114635091z-640x480-otv-eng-sukant-rout-1-2025-07-18-17-16-35.png)
/odishatv/media/member_avatars/uploadimage/library/16_9/16_9_1/PTI_1621847221.jpeg )
Follow Us/odishatv/media/post_attachments/uploadimage/library/16_9/16_9_0/IMAGE_1621349987.jpg)
Centre To Examine Data Of 2-DG Drug Before Adding To National COVID Treatment Protocol
New Delhi: Drug firm Mankind Pharma on Thursday said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
Also Read
/odishatv/media/post_attachments/uploadimage/library/16_9/16_9_3/IMAGE_1625730874.jpg "Covid Vaccines Safe For Pregnant Women, Says Top Odisha Health Official")
/odishatv/media/post_attachments/uploadimage/library/16_9/16_9_3/IMAGE_1625723983.jpg "'Odisha Govt Well Prepared To Fight With Covid-19 Third Wave'")
/odishatv/media/post_attachments/uploadimage/library/16_9/16_9_3/Corona-testing_1618658778.jpg "India Reports 45,892 New Covid Cases In 24 Hours")
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.
"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company said.